Novacyy 2019-05-26 Sd Fix May 2026
Emerging focus on rapid qPCR machines like the genesig® q16 and q32 . 🛠️ Key Strategic Milestones Around May 2019
The core of its microbiology, hematology, and serology offerings. novacyy 2019-05-26 SD
In early 2019, the company successfully raised approximately €785,000 to fund this expansion, showing strong investor confidence despite its small-cap status at the time. Emerging focus on rapid qPCR machines like the
During this period, Novacyt was transitioning from a niche diagnostics player into a more integrated international group. The company focused on three primary pillars: and serology offerings. In early 2019
Novacyt had recently moved to acquire Australian distributor SCD to accelerate its global footprint.
The date , fell in the wake of several major corporate actions that reshaped the company's financial health:
